PCSK9 from basic science discoveries to clinical trials

    Research output: Contribution to journalReview article

    19 Citations (Scopus)

    Abstract

    Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. The PCSK9 saga is unfolding quickly but is far from complete. Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease and the impact that therapies designed to inhibit its action are having in the clinical setting.

    Original languageEnglish (US)
    Pages (from-to)1420-1438
    Number of pages19
    JournalCirculation research
    Volume122
    Issue number10
    DOIs
    StatePublished - May 1 2018

    Fingerprint

    Clinical Trials
    Cardiovascular Diseases
    Drug Discovery
    Lipoproteins
    Therapeutics
    Proprotein Convertase 9

    Keywords

    • Dyslipidemias
    • Hyperlipoproteinemia type II
    • LDL
    • Lipid metabolism
    • Lipoproteins
    • Receptors

    ASJC Scopus subject areas

    • Physiology
    • Cardiology and Cardiovascular Medicine

    Cite this

    PCSK9 from basic science discoveries to clinical trials. / Shapiro, Michael; Tavori, Hagai; Fazio, Sergio.

    In: Circulation research, Vol. 122, No. 10, 01.05.2018, p. 1420-1438.

    Research output: Contribution to journalReview article

    @article{23132b120b094a61b804c16f021a4a1f,
    title = "PCSK9 from basic science discoveries to clinical trials",
    abstract = "Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. The PCSK9 saga is unfolding quickly but is far from complete. Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease and the impact that therapies designed to inhibit its action are having in the clinical setting.",
    keywords = "Dyslipidemias, Hyperlipoproteinemia type II, LDL, Lipid metabolism, Lipoproteins, Receptors",
    author = "Michael Shapiro and Hagai Tavori and Sergio Fazio",
    year = "2018",
    month = "5",
    day = "1",
    doi = "10.1161/CIRCRESAHA.118.311227",
    language = "English (US)",
    volume = "122",
    pages = "1420--1438",
    journal = "Circulation Research",
    issn = "0009-7330",
    publisher = "Lippincott Williams and Wilkins",
    number = "10",

    }

    TY - JOUR

    T1 - PCSK9 from basic science discoveries to clinical trials

    AU - Shapiro, Michael

    AU - Tavori, Hagai

    AU - Fazio, Sergio

    PY - 2018/5/1

    Y1 - 2018/5/1

    N2 - Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. The PCSK9 saga is unfolding quickly but is far from complete. Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease and the impact that therapies designed to inhibit its action are having in the clinical setting.

    AB - Unknown 15 years ago, PCSK9 (proprotein convertase subtilisin/kexin type 9) is now common parlance among scientists and clinicians interested in prevention and treatment of atherosclerotic cardiovascular disease. What makes this story so special is not its recent discovery nor the fact that it uncovered previously unknown biology but rather that these important scientific insights have been translated into an effective medical therapy in record time. Indeed, the translation of this discovery to novel therapeutic serves as one of the best examples of how genetic insights can be leveraged into intelligent target drug discovery. The PCSK9 saga is unfolding quickly but is far from complete. Here, we review major scientific understandings as they relate to the role of PCSK9 in lipoprotein metabolism and atherosclerotic cardiovascular disease and the impact that therapies designed to inhibit its action are having in the clinical setting.

    KW - Dyslipidemias

    KW - Hyperlipoproteinemia type II

    KW - LDL

    KW - Lipid metabolism

    KW - Lipoproteins

    KW - Receptors

    UR - http://www.scopus.com/inward/record.url?scp=85053804028&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=85053804028&partnerID=8YFLogxK

    U2 - 10.1161/CIRCRESAHA.118.311227

    DO - 10.1161/CIRCRESAHA.118.311227

    M3 - Review article

    C2 - 29748367

    AN - SCOPUS:85053804028

    VL - 122

    SP - 1420

    EP - 1438

    JO - Circulation Research

    JF - Circulation Research

    SN - 0009-7330

    IS - 10

    ER -